Advertisement

Topics

Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial

12:19 EDT 17 Apr 2019 | Investing News Network

Precision BioSciences (NASDAQ:DTIL) has announced it has dosed the first patient in its Phase 1/2 a clinical trial of PBCAR0191, which is the company’s first gene-edited allogenic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate. As quoted in the press release: Precision is developing PBCAR0191 in collaboration with Servier, an international pharmaceutical company. PBCAR0191 is … Continued

The post Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial appeared first on Investing News Network.

Original Article: Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial

NEXT ARTICLE

More From BioPortfolio on "Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...